13 completed, 7 recruiting, 6 terminated, 2 withdrawn. 30 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 13, Recruiting 7, Terminated 6, Withdrawn 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Centre Francois Baclesse: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Adapted Physical Activity on a Walking Platform in Elderly Patients HOspitalized for Cancer Surgery Early rehabilitation through Adapted Physical Activity - Oncology, Elderly Patients | Phase 2 | Recruiting | Centre Francois Baclesse | 60 | 2024-03-15 | 2026-01-12 |
| Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy - Tumor, Solid | Phase 2 | Recruiting | Centre Francois Baclesse | 52 | 2024-03-11 | 2026-07-02 |
| HRD Tests for Ovarian cancER tests to determine HRD status - Ovarian Cancer | Phase 2 | Recruiting | Centre Francois Baclesse | 88 | 2024-02-15 | 2025-09-17 |
| Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy bilateral mucosectomy + tonsillectomy, tonsillectomy - Cancer of Head and Neck, Adenopathy | Phase 2 | Recruiting | Centre Francois Baclesse | 72 | 2021-06-30 | 2024-10-15 |
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) perioperative treatment - Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma | Phase 2 | Completed | Centre Francois Baclesse | 67 | 2021-06-28 | 2026-05-08 |
| TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma Talazoparib + Avelumab - Urothelial Carcinoma | Phase 2 | Recruiting | Centre Francois Baclesse | 50 | 2021-06-01 | 2025-09-22 |
| Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse Radiation by protontherapy associated to nanoparticles injection - Recurrent Cancer, Previous Radiation | Phase 2 | Withdrawn | Centre Francois Baclesse | 2021-03-01 | 2025-09-17 | |
| Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy) Essential oils - Nausea and Vomiting, Aromatherapy | Phase 2 | Completed | Centre Francois Baclesse | 96 | 2020-12-14 | 2026-08-17 |
| A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases Steretactic radiotherapy - Metastatic Renal Cell Carcinoma, Radiotherapy | Phase 2 | Recruiting | Centre Francois Baclesse | 77 | 2020-07-01 | 2026-01-13 |
| Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure Cabozantinib - Advanced/Metastatic Cervical Cancer | Phase 2 | Completed | Centre Francois Baclesse | 57 | 2020-01-15 | 2026-07-31 |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab - NSCLC Stage IIIB, NSCLC Stage IV | Phase 2 | Completed | Centre Francois Baclesse | 150 | 2019-09-26 | 2026-05-12 |
| Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal FSRT Stereotactic radiation therapy - Hemorrhagic Brain Metastases | Phase 2 | Recruiting | Centre Francois Baclesse | 46 | 2019-01-16 | 2025-02-11 |
| Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway Carboplatin - Castration-resistant Prostate Cancer, Metastasis | Phase 2 | Completed | Centre Francois Baclesse | 16 | 2018-09-10 | 2026-06-11 |
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Olaparib, Temozolomide (TMZ), IMRT (Intensity Modulated Radiation Therapy) - Malignant Gliomas, Radiotherapy | Phase 1 / Phase 2 | Active not recruiting | Centre Francois Baclesse | 91 | 2017-09-04 | 2025-12-04 |
| A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer ABT-263 - Platinum-resistant or Refractory Ovarian Cancer | Phase 2 | Completed | Centre Francois Baclesse | 47 | 2016-01-01 | 2019-03-19 |
| Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life 5Fluorouracile and Mitomycin-C, Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy - Locally Advanced Anal Canal Cancer | Phase 2 | Completed | Centre Francois Baclesse | 71 | 2015-12-01 | 2026-08-31 |
| Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas F18-choline PET examination - Hyperparathyroidism | Phase 2 | Completed | Centre Francois Baclesse | 28 | 2015-03-01 | 2018-01-04 |
| A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors Tamoxifen, Ralimetinib (LY2228820 dimesylate) - Postmenopausal, Metastatic Breast Cancer | Phase 2 | Terminated | Centre Francois Baclesse | 8 | 2015-01-01 | 2017-05-24 |
| Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy K5-RGD PET, FDG - Non-seminomatous Germ Cell Tumors, Metastasis | Phase 2 | Completed | Centre Francois Baclesse | 16 | 2014-12-01 | 2020-07-09 |
| Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. Acetylsalicylic acid + loperamide, diosmectite + loperamide - Cancer | Phase 2 | Withdrawn | Centre Francois Baclesse | 2014-12-01 | 2015-12-08 |
Showing 20 of 30. Sign in to see all of them.
Breast Neoplasms (7) · Neoplasms (5) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Head and Neck Neoplasms (2) · Recurrence (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Fatigue (1) · Fistula (1) · Glioma (1) · Hereditary Breast and Ovarian Cancer Syndrome (1) · Hyperparathyroidism (1)
Carboplatin (3) · Radiotherapy (3) · Radiotherapy, Intensity-Modulated (2) · Aspirin (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Brachytherapy (1) · Etoposide (1) · Filgrastim (1) · Lapatinib (1) · Loperamide (1) · Mitomycin (1) · Neuropsychological Tests (1) · Oils, Volatile (1) · Pemetrexed (1)
France (29)
Corinne Delcambre (1) · Maya Gutierrez, MD (1)
PMID 29270788, PMID 29635147, PMID 32087691, PMID 34563169, PMID 35123771, PMID 35344040, PMID 35549674, PMID 36434554, PMID 36801605, PMID 38425504, PMID 38830303, PMID 39882966, PMID 40148848, PMID 40340830, PMID 40597907, PMID 41653501, PMID 42637259
2009 (1), 2015 (1), 2017 (1), 2019 (1)